Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).
Public ClinicalTrials.gov record NCT07264517. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Double-masked, Randomized, Vehicle-controlled Study Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 2, multi-site, double-masked, randomized, vehicle-controlled, study designed to evaluate the safety, tolerability, and efficacy in adult participants with DED.
Study identification
- NCT ID
- NCT07264517
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 103 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 3, 2025 (Actual)
- Primary completion
- May 20, 2026 (Actual)
- Completion
- May 20, 2026 (Actual)
- Last update posted
- Jun 16, 2026
2025 – 2026
United States locations
- U.S. sites
- 10
- U.S. states
- 7
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GC2302 Study Site 110 | Glendale | California | 91204 | — |
| GC2302 Study Site 109 | Grove | California | 92843 | — |
| GC2302 Study Site 103 | Newport Beach | California | 92663 | — |
| GC2302 Study Site 105 | Morrow | Georgia | 30260 | — |
| GC2302 Study Site 106 | Carmel | Indiana | 46290 | — |
| GC2302 Study Site 104 | Asheville | North Carolina | 28803 | — |
| GC2302 Study Site 101 | Garner | North Carolina | 27529 | — |
| GC2302 Study Site 107 | Cranberry Township | Pennsylvania | 160166 | — |
| GC2302 Study Site 102 | Memphis | Tennessee | 38119 | — |
| GC2302 Study Site 111 | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07264517, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 16, 2026 · Synced Oct 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07264517 live on ClinicalTrials.gov.